Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions.

Citation data:

Molecular cancer therapeutics, ISSN: 1538-8514, Vol: 16, Issue: 10, Page: 2281-2291

Publication Year:
2017
Captures 13
Readers 13
Citations 3
Citation Indexes 3
PMID:
28775145
DOI:
10.1158/1535-7163.mct-17-0259
Author(s):
Dalal, Kush; Che, Meixia; Que, Nanette S; Sharma, Aishwariya; Yang, Rendong; Lallous, Nada; Borgmann, Hendrik; Ozistanbullu, Deniz; Tse, Ronnie; Ban, Fuqiang; Li, Huifang; Tam, Kevin J; Roshan-Moniri, Mani; LeBlanc, Eric; Gleave, Martin E; Gewirth, Daniel T; Dehm, Scott M; Cherkasov, Artem; Rennie, Paul S Show More Hide
Publisher(s):
American Association for Cancer Research (AACR)
Tags:
Medicine; Biochemistry, Genetics and Molecular Biology
article description
Human androgen receptor (AR) is a hormone-activated transcription factor that is an important drug target in the treatment of prostate cancer. Current small-molecule AR antagonists, such as enzalutamide, compete with androgens that bind to the steroid-binding pocket of the AR ligand-binding domain (LBD). In castration-resistant prostate cancer (CRPC), drug resistance can manifest through AR-LBD mutations that convert AR antagonists into agonists, or by expression of AR variants lacking the LBD. Such treatment resistance underscores the importance of novel ways of targeting the AR. Previously, we reported the development of a series of small molecules that were rationally designed to selectively target the AR DNA-binding domain (DBD) and, hence, to directly interfere with AR-DNA interactions. In the current work, we have confirmed that the lead AR DBD inhibitor indeed directly interacts with the AR-DBD and tested that substance across multiple clinically relevant CRPC cell lines. We have also performed a series of experiments that revealed that genome-wide chromatin binding of AR was dramatically impacted by the lead compound (although with lesser effect on AR variants). Collectively, these observations confirm the novel mechanism of antiandrogen action of the developed AR-DBD inhibitors, establishing proof of principle for targeting DBDs of nuclear receptors in endocrine cancers. .